Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma
Treatment with second-line lisocabtagene maraleucel (liso-cel; Breyanzi) yielded a response rate of 80% for patients with relapsed or refractory large B-cell lymphoma (LBCL) who were not candidates for hematopoietic stem cell transplant, the phase II PILOT study showed. Among 61 evaluable patients with PET-positive disease, 54% achieved a complete response with the chimeric antigen receptor […]